λ νΈλ μ
λ νΈλ μμ ν©μ±λ μ§μν **μμ μ€νΌμ€μ΄λ κΈΈνμ **μ λλ€. ꡬ쑰μ μΌλ‘ λ λ‘μκ³Ό μ μ¬νμ§λ§ 경ꡬ μ체μ΄μ©λ₯ μ΄ ν¨μ¬ λκ³ μμ© μκ°μ΄ λ κΉλλ€. μμνμμλ μ£Όλ‘ λ€μκ³Ό κ°μ **κ°λ° νλ μ₯μ **μ 보쑰 μΉλ£μ λ‘ νκ° μΈ(off-label) μ¬μ©λ©λλ€: - λ§λ¨ ν₯κΈ° νΌλΆμΌ (ν₯κΈ° μ‘μμ’ ) - 꼬리 μ«κΈ° - μꡬ리 λΉ¨κΈ° - κΈ°ν μν΄ λλ μλ νλ **μμ μμ **: νλ μνμμ μ΄ μ½λ¬Όμ μ¬μ©νλ κ·Όκ±°λ μλ νλμ΄ λ΄μΈμ± μ€νΌμ€μ΄λ(μλν)μ λ°©μΆμ μκ·Ήνμ¬ νλμ κ°ννλ€λ κ°μ€μμ λΉλ‘―λ©λλ€. λ νΈλ μμ μ΄λ¬ν μμ©μ²΄λ₯Ό μ°¨λ¨ν¨μΌλ‘μ¨ λ΄μ "보μ"μ μ κ±°νμ¬ κ°λ° νλμ μκ±°νλ λ° λμμ μ€λλ€.
μμ© κΈ°μ : Naltrexone acts as a **competitive antagonist** at opioid receptors, with the highest affinity for **ΞΌ (mu)** receptors, followed by **ΞΊ (kappa)** and **Ξ΄ (delta)** receptors. - **Mechanism in Behavior Disorders**: Compulsive behaviors β Release of endogenous endorphins β Binding to ΞΌ-receptors β Reinforcement/Analgesia. - Naltrexone **blocks** these receptors β Prevents endorphin binding β Eliminates the auto-reinforcing reward loop of the stereotypic behavior.
λλ¬Ό μ’ λ³ μ©λ
- As adjunctive therapy in behavior disorders Β· 25-50 mg/cat Β· PO Β· q24h Β· Note: has a bitter taste
- As adjunctive therapy in behavior disorders (tail chasing or excessive licking) Β· 1-2 mg/kg Β· PO Β· daily Β· Long-term therapy may be required Β· First give 0.01 mg/kg SC of naloxone to determine if narcotic antagonists may be effective, if so give naltrexone.
- As adjunctive therapy in behavior disorders Β· 2-5 mg/kg Β· PO Β· once daily
- As adjunctive therapy in behavior disorders Β· 1-2.2 mg/kg Β· PO Β· q8-12h
- For the adjunctive treatment of acral pruritic dermatitis Β· 2.2 mg/kg Β· PO Β· once daily Β· one-month trial Β· Some dogs exhibit drowsiness and minor changes in behavior. 50-60% of patients have benefited. Expense is of concern.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
μ΄μλ°μ
- Drowsiness
- Minor changes in behavior
- Elevated hepatic enzymes (AST, ALT)
μ½λ¬Ό μνΈμμ©
- Opioid partial-agonists (e.g., butorphanol, pentazocine, nalbuphine) Β· May antagonize the effects of these agents, including respiratory depression and analgesia.
- Clonidine Β· Naltrexone may reduce the hypotensive and bradycardic effects of clonidine.
- Yohimbine Β· Naltrexone may increase the CNS effects of yohimbine (anxiety, tremors, nausea, palpitations) and increase plasma cortisol levels.
λͺ¨λν°λ§
- Clinical efficacy (reduction in stereotypic behaviors)
- Liver enzymes (AST, ALT) if using very high doses with prolonged therapy
κ³Όμ©λ
Specific overdosage information is not provided in the monograph. However, as an opioid antagonist, massive overdoses could theoretically cause dysphoria or precipitate withdrawal in opioid-dependent patients. Monitor liver enzymes if very high doses are ingested.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.